Abstract
We read with great interest the manuscript by Lobo de Figueiredo-Pontes and colleagues (Lobo de Figueiredo-Pontes et al., 2021) on the potential clinical usefulness of NK cell-derived IFNγ inhibition to favor engraftment in allogeneic hematopoietic stem cell transplantation (HSCT). Indeed, the role of IFNγ in regulating hematopoiesis during acute or chronic inflammation through modulation of transcription factor expression and perturbation of cytokine signaling is well characterized (Merli et al., 2021).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
